Corvus publishes final Phase 1/1b soquelitinib data in Blood supporting Phase 3 relapsed/refractory PTCL trial

Corvus reported peer-reviewed final Phase 1/1b data for soquelitinib in T-cell lymphoma published in Blood; results were previously generated, not future-presented.

The study showed durable anti-tumor activity in heavily pre-treated patients, including complete responses, with a tolerable safety profile.

The findings support ongoing registration Phase 3 testing in relapsed or refractory peripheral T-cell lymphoma versus physician’s choice chemotherapy options.

Mechanism data linked activity to immune rebalancing effects in blood and tumor samples, supporting expansion into inflammatory diseases.

The company is enrolling a Phase 2 trial in atopic dermatitis, with additional trials planned in hidradenitis suppurativa and asthma.